Know Cancer

or
forgot password

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample


N/A
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample


Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective
in most patients. The reason for this inconsistency, and the conditions necessary for
successful immunotherapy, are not well understood. Our studies in animal tumor models
indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a
preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma
expression in tumor indicate such an immune response. We therefore plan to evaluate the
existing immune response in human tumor samples in an effort to identify those patients most
likely to respond to therapy with IL-12.


Inclusion Criteria:

Any adult patient with a tumor who is scheduled to undergo surgery to
either remove or biopsy the tumor.

Exclusion Criteria:Patients without tumor and pediatric patients (children) will be
excluded.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Jeffrey A. Norton

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

SU-11072007-830

NCT ID:

NCT00568867

Start Date:

September 2006

Completion Date:

December 2008

Related Keywords:

  • Cancer

Name

Location

Stanford University School of MedicineStanford, California  94305-5317